Ausgangsorgan Dysfunktion, die Standard vorschreibt methotrexate / vinorelbin adjuvant oder aff...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | RF-IMT-ORGAN-DYSFUNCTION |
|---|---|
| Art | Warnhinweis |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Erkrankungen | DIS-IMT |
| Quellen | SRC-NCCN-SARCOMA |
Ursprung der Roten Flagge
| Begriffsbestimmung | Baseline organ dysfunction precluding standard methotrexate / vinorelbine adjuvant or affecting crizotinib / lorlatinib / entrectinib dosing in IMT: bilirubin >3× ULN (TKI-class hepatic clearance, vinorelbine metabolism), CrCl <30 mL/min (methotrexate contraindicated), LVEF <50% (lorlatinib hyperlipidemia + cardiac concerns), QTc >480 ms (crizotinib / lorlatinib QT prolongation), or DLCO <60% (crizotinib pneumonitis signal). |
|---|---|
| Klinische Richtung | Eskalation |
| Kategorie | Organdysfunktion |
Logik auslösen
{
"any_of": [
{
"comparator": ">=",
"finding": "bilirubin_ratio_to_uln",
"threshold": 3
},
{
"comparator": "<",
"finding": "creatinine_clearance_ml_min",
"threshold": 30
},
{
"comparator": "<",
"finding": "lvef_percent",
"threshold": 50
},
{
"comparator": ">",
"finding": "qtc_ms",
"threshold": 480
},
{
"comparator": "<",
"finding": "dlco_percent",
"threshold": 60
}
],
"type": "lab_value"
}
Anmerkungen
Crizotinib + lorlatinib both prolong QTc — baseline ECG mandatory; hold if QTc >500 ms. Crizotinib has documented pneumonitis signal (~1-2% Gr3+) — DLCO <60% increases risk of clinically meaningful toxicity. Lorlatinib hyperlipidemia + weight gain + cognitive effects documented; baseline lipid panel + LVEF measurement recommended. Hepatic dose reductions per FDA labels for severe impairment. Methotrexate / vinorelbine adjuvant (used in fusion-negative or pre- TKI era IMT) requires standard cytotoxic monitoring.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.